Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the benefit of treatment with oral dose of Ibodutant
(code: MEN 15596) on IBS symptoms and the safety and tolerability of this therapy.